• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

    2/14/25 3:00:13 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNY alert in real time by email
    For Immediate Release:
    February 14, 2025

    Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Merilog helps to lower mealtime blood sugar spikes to improve control of blood sugar in people with diabetes. The approval is for both a 3 milliliter (mL) single-patient-use prefilled pen and a 10 milliliter (mL) multiple-dose vial.

    Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved in 2021 by the FDA. Approval of biosimilar products can increase patient access to safe and effective treatment options.    

    “The FDA has now approved three biosimilar insulin products to treat diabetes,” said Peter Stein, M.D., director of the Office of New Drugs in the FDA’s Center for Drug Evaluation and Research. “Today’s approval highlights our continued efforts to improve the efficiency of the biosimilar approval process to help support a competitive marketplace and increase options for costly treatments, like insulin. Increasing access to safe, effective and high-quality medications at potentially lower cost remains a continued priority for the FDA.”  

    Biological products include medications for treating many serious illnesses and chronic health conditions, including diabetes. A biosimilar is a biological product that is highly similar to, and has no clinically meaningful differences from, a biological product already approved by the FDA (also called the reference product). Patients can expect the same safety and effectiveness from the biosimilar as from the reference product. To date, the FDA has approved 65 biosimilar products for a variety of health conditions.

    More than 38 million people in the U.S. have been diagnosed with diabetes, a disease that occurs when blood glucose (sugar) is too high. Approximately 8.4 million Americans rely on insulin therapy, either rapid-acting and/or long-acting, to manage diabetes. Insulin, a hormone made by the pancreas, helps glucose get into a person’s cells to be used for energy. With diabetes, the pancreas doesn’t make enough insulin to keep blood sugar levels in the normal range, which can lead to serious health problems for patients.

    “For the millions of people who rely on daily injections of insulin for treatment of diabetes, having a biosimilar option for their rapid-acting insulin injection can truly make a difference, as biosimilar products have the potential to increase access to these life-saving medications,” said Sarah Yim, M.D., director of the Office of Therapeutic Biologics and Biosimilars in the FDA’s Center for Drug Evaluation and Research.

    Like Novolog, Merilog should be administered within five to ten minutes prior to the start of a meal. Merilog is administered subcutaneously (under the skin) by injection into the stomach, buttocks, thighs or upper arms. Dosing of Merilog should be individualized and adjusted based on the patient’s needs.

    Merilog may cause serious side effects, including hypoglycemia (low blood sugar), severe allergic reactions and hypokalemia (low potassium in blood). Other common side effects may include injection site reactions, itching, rash, lipodystrophy (skin thickening or pitting at the injection site), weight gain and swelling of hands and feet.

    The FDA granted approval of Merilog to Sanofi-Aventis U.S. LLC.

    Related Information

    Related Information
    • Biosimilars
    • Purple Book Database of Licensed Biological Products
    • FDA Approves First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes
    • Biosimilars: What Patients With Diabetes Need to Know

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.


    Inquiries

    Media:
    Cherie Duvall-Jones
    301-357-0607
    Consumer:
    888-INFO-FDA

    Get the next $SNY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SNY

    DatePrice TargetRatingAnalyst
    4/15/2025$65.00Outperform
    Exane BNP Paribas
    3/21/2025$65.00Neutral
    Goldman
    1/30/2025Sell → Hold
    Deutsche Bank
    7/26/2024$55.00 → $60.00Buy
    Argus
    1/23/2024$55.00Equal-Weight
    Morgan Stanley
    1/16/2024Buy
    UBS
    12/5/2023Overweight → Neutral
    JP Morgan
    10/30/2023Buy → Hold
    Stifel
    More analyst ratings

    $SNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

      For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

      3/28/25 10:17:55 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

      For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

      2/14/25 3:00:13 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

      Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

      11/4/24 4:49:34 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on Sanofi with a new price target

      Exane BNP Paribas initiated coverage of Sanofi with a rating of Outperform and set a new price target of $65.00

      4/15/25 12:40:46 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Sanofi with a new price target

      Goldman initiated coverage of Sanofi with a rating of Neutral and set a new price target of $65.00

      3/21/25 8:12:02 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi upgraded by Deutsche Bank

      Deutsche Bank upgraded Sanofi from Sell to Hold

      1/30/25 3:33:45 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    SEC Filings

    See more
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      7/2/25 8:25:36 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Sanofi

      11-K - Sanofi (0001121404) (Filer)

      6/27/25 4:52:49 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Sanofi

      11-K - Sanofi (0001121404) (Filer)

      6/27/25 4:49:46 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts

      New fund supports nonprofit partners working to address social drivers of health and strengthen community well-beingCAMBRIDGE, Mass., June 26, 2025 /PRNewswire/ -- Sanofi today announced it has awarded over $1 million in grants through its inaugural Healthy Futures Solution Fund to support local nonprofits across Massachusetts that are advancing community-led solutions to improve health and well-being in historically undersupported communities. The initiative is part of Sanofi's broader commitment to improve equitable access to healthcare by addressing structural factors, such as lack of access to housing, food, and behavioral health. Launched earlier this year, the Fund strategically inves

      6/26/25 8:00:00 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

      TORONTO, June 9, 2025 /CNW/ - Sanofi Canada today announced the appointment of James Guy as Country Lead, Canada and General Manager, Specialty Care. In this role, Guy will lead Sanofi's Canada Country Council, which manages the operations of the company's three business units and functions. Guy will also head the Specialty Care business unit in Canada. James Guy Country Lead, Canada and General Manager, Specialty Care "This is an exciting time in Sanofi's history, with the potential for our promising pipeline to deliver several scientific breakthroughs that can improve healt

      6/9/25 10:00:00 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

      Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolioPARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU

      6/2/25 1:25:00 AM ET
      $BPMC
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Sanofi converted options into 3,088,502 units of Common Stock and bought $1,000,005 worth of Common Stock (66,667 units at $15.00)

      4 - Sanofi (0001121404) (Reporting)

      8/2/21 8:34:24 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by Sanofi

      3 - Sanofi (0001121404) (Reporting)

      7/28/21 8:32:04 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Financials

    Live finance-specific insights

    See more
    • Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

      Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolioPARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU

      6/2/25 1:25:00 AM ET
      $BPMC
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

      - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

      5/21/25 7:30:46 PM ET
      $SNY
      $VIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

      ― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Industry veteran, Patrick Horn M.D., Ph.D., appointed as chief medical officer ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, toda

      5/13/24 7:00:00 AM ET
      $FULC
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Leadership Updates

    Live Leadership Updates

    See more
    • Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

      TORONTO, June 9, 2025 /CNW/ - Sanofi Canada today announced the appointment of James Guy as Country Lead, Canada and General Manager, Specialty Care. In this role, Guy will lead Sanofi's Canada Country Council, which manages the operations of the company's three business units and functions. Guy will also head the Specialty Care business unit in Canada. James Guy Country Lead, Canada and General Manager, Specialty Care "This is an exciting time in Sanofi's history, with the potential for our promising pipeline to deliver several scientific breakthroughs that can improve healt

      6/9/25 10:00:00 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

      ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

      6/6/24 7:00:00 AM ET
      $AZN
      $IMAB
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi Bridging the Gap between the Homeless and Society via Futsal

      Sanofi hosted the founding ceremony of the homeless futsal club ‘Dream' and organized a friendly match as a part of the Helping Hands program Sanofi employees and ‘Dream' members interacted through the friendly match Sanofi has carried out social responsibility activities targeting the homeless and housing vulnerable groups since 2011 Sanofi in Korea[1], the Korean subsidiaries of the global healthcare company Sanofi, hosted the founding ceremony of the homeless futsal club ‘Dream' together with Dalpengyee, a nonprofit organization, to promote self-sufficiency among the homeless. At the founding ceremony of the ‘Dream', held in Seongsu-dong, Seoul on the 17th, the club's first game

      10/17/23 9:00:00 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sanofi

      SC 13G/A - Sanofi (0001121404) (Subject)

      11/7/24 2:49:36 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Sanofi

      SC 13G - Sanofi (0001121404) (Filed by)

      5/31/24 4:30:55 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Sanofi (Amendment)

      SC 13G/A - Sanofi (0001121404) (Subject)

      2/14/24 3:57:49 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care